Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Economic information and modeling reportBudget impact model

Epidemiology and eligible population inputs

13 evidence topics · 11 sources

Budget impact model of ficerafusp alfa: eligible population inputs

No evidence found.

Estimated new cases and deaths in the United States in 2026 by head and neck site
SiteEstimated new cases, both sexesEstimated deaths, both sexes
Oral cavity and pharynx“60,480”“13,150”
Tongue“20,420”“3,560”
Mouth“15,810”“3,340”
Pharynx“21,760”“4,760”
Other oral cavity“2,490”“1,490”
Larynx“12,290”“3,960”
Stage at diagnosis of oral cavity and pharynx cancer
Stage at diagnosisPercent of cases
Localized (confined to primary site)“26%”
Regional (spread to regional lymph nodes)“55%”
Distant (cancer has metastasized)“12%”
Unknown (unstaged)“6%”
Stage at diagnosis of laryngeal cancer
Stage at diagnosisPercent of cases
Localized (confined to primary site)“49%”
Regional (spread to regional lymph nodes)“30%”
Distant (cancer has metastasized)“15%”
Unknown (unstaged)“6%”
Share of oropharyngeal squamous cell carcinoma attributable to HPV in the United States
Measure, oropharynx, 2012 to 2016Value
Reported HPV-associated cancers, average annual number“19,000”View highlighted excerpt for this quote
Attributable to 9vHPV-targeted types, number (%)“12,600 (66)”View highlighted excerpt for this quote
Attributable to other HPV types, number (%)“900 (5)”View highlighted excerpt for this quote
HPV-negative, number (%)“5,500 (29)”View highlighted excerpt for this quote